Aimmune Therapeutics Enrolls First Patient in RAMSES (ARC007), a Phase 3 Clinical Trial of AR101 for the Treatment of Peanut Allergy by Carolyn Helms | May 11, 2017 | Portfolio News
Collegium Reports First Quarter Financial Results and Provides Corporate Update by Carolyn Helms | May 10, 2017 | Portfolio News
Aimmune Therapeutics Announces First Quarter 2017 Financial Results by Carolyn Helms | May 8, 2017 | Portfolio News
Corcept Therapeutics Annnounces First Quarter 2017 Financial Results, Raises 2017 Revenue Guidance and Provides Corporate Update by Carolyn Helms | May 1, 2017 | Portfolio News
Kala Pharmaceuticals Announces Positive Results from Confirmatory Phase 3 Trial of KPI-121 1% Following Cataract Surgery by Carolyn Helms | May 1, 2017 | Portfolio News
